IDL Biotech AB share has been listed on Spotlight Stock Market since (26/6 2000) under the ticker (IDL B) and is traded through banks and stockbrokers.
In accordance with all regulations, IDL issues quarterly reports to the market and distributes the annual report to all shareholders. All this information is in Swedish.
The share holder’s annual meeting is usually held in Stockholm, and is announced accordingly.
2020-10-15 IDL Biotech third quarter report 2020
2021-02-18 IDL Biotech fourth quarter report and Year-end report 2020
Charlotte Berg leaves the position as CEO of IDL Biotech AB (publ)
IDL Biotech's CEO, Charlotte Berg, has informed the Board that, after more than ten years at the company, she wishes to resign as CEO to start another assignment in a non-competing company.
Information från årsstämman den 27 maj 2020
IDL Biotech AB (publ) avhöll årsstämma på onsdagen den 27 maj 2020.
Årsstämma hålls den 27 maj 2020 kl. 15.00 på Piperska Muren, Scheelegatan 14, 112 28 Stockholm.
IDL Biotech signs new distribution agreement with Beckman Coulter, which gives the distributor global sales rights for the company's tumor markers on the ELISA manual platform.
Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, ”says Charlotte Berg, CEO of IDL Biotech. IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.